Stability Analysis of Proteins for the Biopharmaceutical Industry
The biggest class of biopharmaceuticals on the market is monoclonal antibodies (mAb) and their specific binding nature provides an opportunity to use them to modulate pharmaceutically-relevant molecule activity to control or prevent disease.
A key difference between traditional small molecule pharmaceuticals and biopharmaceuticals is that the latter needs to be processed and delivered in liquid form. Proteins are notoriously unstable in solutions, so approaches need to be developed where these biotherapeutic molecules can be manufactured and stored for long periods in solution without degrading. This is where protein stability has proved invaluable in the development and manufacture of biotherapeutics.
Download to find out more.